Internal Medicine
Online ISSN : 1349-7235
Print ISSN : 0918-2918
ISSN-L : 0918-2918
64 巻, 17 号
選択された号の論文の27件中1~27を表示しています
REVIEW ARTICLE
ORIGINAL ARTICLES
  • Tomoaki Nishikawa, Akinori Higaki, Yutaro Okada, Rikako Horie, Yasuhis ...
    2025 年64 巻17 号 p. 2534-2540
    発行日: 2025/09/01
    公開日: 2025/09/01
    [早期公開] 公開日: 2025/03/15
    ジャーナル オープンアクセス
    電子付録

    Objective Anemia frequently complicates cardiovascular disease (CVD) and is associated with high mortality rates. A bioelectrical impedance analysis (BIA) is a noninvasive method for measuring human body composition. A direct association between serum hemoglobin (Hb) levels and the extracellular water-to-total body water (ECW/TBW) ratio, as measured by a BIA in patients with diabetes, has been reported. However, the predictive value of the ECW/TBW ratio for detecting anemia in patients with CVD has not been fully elucidated.

    Methods We conducted a study involving consecutive patients admitted to our cardiology department from January 1, 2021, to December 31, 2022. A BIA was performed once during hospitalization for all patients, whenever possible. The correlation between the Hb level and ECW/TBW ratio was assessed. The predictive accuracy for anemia was evaluated using a receiver operating characteristic (ROC) curve analysis.

    Results The ECW/TBW ratio was significantly higher in the anemia group than in the non-anemia group [0.41 (0.40, 0.41) vs. 0.39 (0.38, 0.40), p<0.001]. The ECW/TBW ratio exhibited a significant negative correlation with Hb, with an R value of 0.57 and a p value of <0.01. However, this correlation coefficient decreased to 0.45 among subjects with B-type natriuretic peptide (BNP) levels ≥200 pg/mL. The area under the ROC curve (AUC) for the ECW/TBW ratio for detecting anemia was 0.83. However, its predictive performance decreased in patients with BNP levels exceeding 200 pg/mL, with an AUC of 0.71.

    Conclusion The BIA-derived ECW/TBW ratio is a valuable predictor of anemia in patients with CVD, provided BNP levels are not elevated.

  • Joichi Usui, Kouichi Hirayama, Masaki Kobayashi, Satoshi Suzuki, Itaru ...
    2025 年64 巻17 号 p. 2541-2548
    発行日: 2025/09/01
    公開日: 2025/09/01
    [早期公開] 公開日: 2025/02/22
    ジャーナル オープンアクセス

    Objective We conducted a prospective, randomized controlled, open-label study to investigate the efficacy of a combination of cyclosporine and low-dose prednisolone in patients with idiopathic membranous nephropathy (IMN).

    Methods We recruited biopsy-proven IMN patients with nephrotic syndrome who had never been treated with immunosuppressants. The patients were randomized into 2 groups treated after randomization with cyclosporine (3 mg/kg/day) alone or with an oral low-dose corticosteroid (prednisolone 15 mg/day) for 24 months.

    Results We recruited 30 patients with IMN and nephrotic-range proteinuria, 28 of whom were included in this study. Fourteen patients were randomized for treatment with only cyclosporine (Group A), and 14 were randomized for treatment with cyclosporine plus low-dose corticosteroids (Group B). Cyclosporine monotherapy induced remission in 12 of the 14 patients in Group A, including partial remission in 7 patients (50.0%) and complete remission in 5 patients (36.7%). In Group B, 12 of 14 patients achieved proteinuria remission, including 11 (78.6%) with complete remission and 1 (7.1%) with partial remission. Although there was no marked difference in the overall remission rate, the complete remission rate was significantly higher in Group B than in Group A (p=0.02). Furthermore, there was a statistically significant difference between the groups in the time from the start of the study to complete remission (10.2±7.8 months in Group A; 9.5±6.1 months in Group B, p=0.03).

    Conclusion The combination of cyclosporine and low-dose corticosteroid treatment is an effective and important option in the management of patients with IMN with nephrotic-range proteinuria, either as an initial therapy or as a long-term treatment.

  • Hiroshi Kobe, Miyuki Okuda, Takeshi Yoshida, Toru Oga, Kenichi Ito
    2025 年64 巻17 号 p. 2549-2556
    発行日: 2025/09/01
    公開日: 2025/09/01
    [早期公開] 公開日: 2025/02/22
    ジャーナル オープンアクセス
    電子付録

    Objective Short-acting β2 agonists (SABAs) are key drugs for the treatment of asthma and chronic obstructive pulmonary disease (COPD). A high-flow nasal cannula (HFNC) is widely used for respiratory failure. Recently, a consensus statement on inhalation therapy with HFNC has been published. However, information regarding the real-world state of inhalation therapy practices in Japan is lacking.

    Methods An anonymous online questionnaire survey endorsed by three Japanese associations (the Japanese Respiratory Society, Japanese Society of Intensive Care Medicine, and Japanese Society of Respiratory Care Medicine) was administered from October to November 2023. Responses were stratified into three questions: Question A, "Do you routinely treat patients with asthma and COPD?" Question B "Do you routinely perform high-flow therapy?"; and Question C "How do you provide inhaled SABAs during high-flow therapy in patients with asthma or COPD?"

    Patients This questionnaire was distributed to all members of the three societies.

    Results Of the 567 participants who completed the questionnaire, 387 responded to all 3 questions. When a nebulizer was included in high-flow devices, the frequencies of using an ultrasonic nebulizer, jet, vibrating mesh, other, or not performing nebulization were 49.1%, 30.8%, 5.4%, 0.5%, and 14.2%, respectively; when a nebulizer was included in high-flow devices, these frequencies were 24.0%, 11.1%, 16.0%, 0%, and 48.9%, respectively.

    Conclusion Various techniques for inhalation therapy are being employed, revealing a discrepancy between current practices in Japan and the recommendations outlined in the consensus statement.

CASE REPORTS
PICTURES IN CLINICAL MEDICINE
feedback
Top